Purdue Pharma Strikes Licensing Deal For OxyContin

Law360, New York (September 2, 2008, 12:00 AM EDT) -- Purdue Pharma LP and generics maker Mallinckrodt Inc. have struck a deal that will allow Mallinckrodt to market and sell its cheaper version of the brand-name painkiller OxyContin for a licensing fee.

Putting to rest litigation in the U.S. District Court for the Southern District of New York, Mallinckrodt agreed to acknowledge that Purdue's patents for OxyContin are valid and enforceable. Purdue, in exchange, will permit Mallinckrodt to sell limited amounts of an oxycodone hydrochloride extended-release medication, the generic equivalent to OxyContin, for a time period...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.